When it comes to impactful, evidence-based healthcare, the conversation does not happen in isolation. Increasingly, it takes place across borders. One of the forums for this dialogue is the ISPOR Nordic Chapter, the Nordic voice within the international ISPOR network.
The Nordic Chapter brings together a wide range of stakeholders from across the Nordic countries, providing a platform where research, policy-making and everyday healthcare practice meet. The community includes around 100 members who share a common goal: advancing more effective, sustainable and evidence-based healthcare.
Medaffcon is also actively involved in the work of the ISPOR Nordic Chapter. From Medaffcon, Medaffcon Sweden’s Managing Director Lisse-Lotte Hermansson and Principal Consultant Jarmo Hahl participate in developing the network and its activities.
Hermansson serves as a member of the Nordic Chapter Board and leads a working group focused on artificial intelligence (WS5: AI). Hahl, in turn, chairs a working group dedicated to Joint Clinical Assessment (JCA) and related EU initiatives (WS3: Collaboration on EU JCA in the Nordics).
The working groups are carefully composed: each group includes eight members representing different Nordic countries and a variety of organisations, ensuring diverse perspectives and truly impactful discussions. At the heart of the Nordic Chapter’s work are the most pressing and relevant issues in healthcare today.
“At the core of our activities are cost-effectiveness assessment, the appropriate allocation of healthcare resources, patient-reported outcomes, and the evaluation of new treatments and technologies in a Nordic context,” Hahl explains.
In practice, this translates into active and goal-oriented engagement. The Nordic Chapter regularly organises meetings and workshops that provide up-to-date insights, support professional development and offer valuable networking opportunities.
“The Nordic Chapter acts as a bridge between research and real-world decision-making at the point where science meets everyday healthcare,” Hermansson summarises.
One of the Chapter’s key ambitions is to strengthen its visibility at the international level. The aim is to ensure that Nordic Chapter–led panel discussions, posters or presentations are regularly featured at international ISPOR events, reflecting the network’s ongoing work and expertise.
In addition, the network meets quarterly for inspiring and topical online sessions via Teams. These meetings provide a forum for sharing perspectives, sparring ideas and jointly shaping the future of Nordic healthcare.
We warmly encourage you to join the ISPOR Nordic Chapter and become part of this dynamic community. As a member, you will have the opportunity to contribute to meaningful discussions, enhance your professional network, and help shape the future of health economics and outcomes research in the Nordics.
There are several active workstreams within the Chapter addressing key topics: if you’re interested in contributing to the work on Joint Clinical Assessment (WS3: Collaboration on EU JCA in the Nordics) or Artificial Intelligence (WS5: AI), we invite you to reach out to Jarmo Hahl (WS3) or Lisse-Lotte Hermansson (WS5), respectively, to explore how you can get involved.
What do you remember from the ISPOR conference in November? Read our overview of the latest ISPOR Europe conference and see which topics are worth following in 2026!
The first ISPOR Nordic Chapter Inspirational Meeting brought together Nordic experts in cost-effectiveness, reimbursement, and real-world evidence (RWE) in April 2025. Sweden’s TLV Updates Reimbursement Model for Rare Diseases
The objective is to improve access to health data for research and innovation, but the proposal raises concerns about increased administrative burden and the role of industry within the model.
The monitoring and diagnosis of diabetic kidney disease are often insufficient in Finland. This is confirmed by two real-world evidence (RWE) studies.
What do you remember from the ISPOR conference in November? In this overview we discuss which topics are worth following in 2026.
Principal Consultant
MSc (Economics)
+358 40 139 4001
jarmo.hahl@medaffcon.com
Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.
Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.
“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.
Country Director Sweden
M.Sc (Econ.) & M.Sc (Health Econ)
+46 73 447 47 27
lisse-lotte.hermansson@medaffcon.com
Lisse-Lotte started at Medaffcon 1st of October 2024. Previously she was at a Swedish-German company as CSO Chief Scientific Officer, consulting European companies about Nordic health data opportunities and market access. She has a M.Sc (Econ.) from Helsingin School of Economics and a M.Sc (Health Econ) from Karolinska. Additionally a Ph.D student at the University of Turku in Health Economics. She has obtained a long experience from global pharma and medtech. She has lived over 20 years in Sweden.
The current development gives new possibilities to utilise data. With AI we can produce synthetic data and build digital twins that can actually support drug development and support healthcare providers. Innovative solutions are only useful if they are adopted to daily practice.
Old ways of working will vanish and RWD will be acknowledged as an excellent option or support for RCTs. As RWD is enabling more cost-effective evidence generation for new treatments. Treatments need to be more personalised so that the right drugs, diagnostics and devices are used for the right patients at the right time.